Bar­gain sale con­tin­ues: As­traZeneca of­floads three res­pi­ra­to­ry drugs to Co­vis in $350M deal

In its sec­ond di­vesti­ture move with­in a week, As­traZeneca is bring­ing in $350 mil­lion by sell­ing three as­sets to Co­vis Phar­ma.

Zug, Switzer­land-based Co­vis first ac­quired US rights to Alvesco, Om­naris and Ze­ton­na in 2017 to beef up a spe­cial­ty fran­chise in the res­pi­ra­to­ry and al­ler­gy ar­eas. It can now com­mer­cial­ize the drugs out­side of the US as well as keep US roy­al­ties to it­self.

Alvesco is an in­haled main­te­nance ther­a­py for asth­ma, while Om­naris and Ze­ton­na are nasal sprays for sea­son­al and peren­ni­al rhini­tis. In 2017, the trio record­ed a com­bined prod­uct sales of $106 mil­lion, ac­cord­ing to As­traZeneca.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER